Psyence Biomedical Ltd (PBM) Stock Price, Quote & News

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 346 7764

Website: www.psyencebiomed.com

Address:

121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada

Alarusso68 Apr. 1 at 7:07 PM

$PBM this stock and company are 🐃💩

0 · Reply

Tradetime3472 Apr. 1 at 1:31 PM

$PBM Texas recent rejected the current applicants, which means they haven’t found a supplier that meets their standards yet. Psyence is uniquely positioned because they already have GMP-grade, naturally sourced ibogaine HCl ready to go..which is exactly what a state-run research program would need to meet pharmaceutical standards. The fact that Texas is now proceeding with their own research program rather than waiting on a drug company actually opens the door wider for a supply partnership rather than closing it. They’ll still need a compliant ibogaine source… they just cut out the middleman drug company.

0 · Reply

OwlKing Mar. 29 at 6:00 PM

$LASE $APVO $PBM $RAYA &

0 · Reply

TradeWithCreed Mar. 27 at 8:24 PM

$APVO $LASE $RAYA $PBM buls

0 · Reply

erb71 Mar. 27 at 11:21 AM

$PBM An intriguing view: Slopes between rallies' highs since last July appear to be flattening (from negative to almost 0). Let's see if the next slope turns positive and signals the start of a potential upward trend in the coming days. (Not advice, just chart observations)

0 · Reply

Jack_Horway Mar. 27 at 2:35 AM

$PBM

0 · Reply

Itradedbadly Mar. 26 at 11:26 PM

$PBM in for 5200 shares. Will comment again when it is worth pennies or the world finally accepts psilocybin.

0 · Reply

Jbjb90 Mar. 26 at 5:21 PM

$PBM all we need is some positive news and volume and were back above 4-5

0 · Reply

Jack_Horway Mar. 16 at 4:14 PM

$PBM hlding for the long run!!!! just like bright minds!

0 · Reply

Dman_22 Mar. 15 at 9:08 PM

$PBM the face that this thing is still below $10-$20 a share right now is mind blowing ?!?! Only a matter of time with all the positive results and good news coming out this year ! Just hold on people good times ahead I promise !😎👌

0 · Reply

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Mar 3, 2026, 9:15 AM EST - 4 weeks ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Feb 20, 2026, 5:20 PM EST - 6 weeks ago

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Feb 17, 2026, 9:15 AM EST - 6 weeks ago

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Feb 13, 2026, 6:30 PM EST - 7 weeks ago

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Feb 11, 2026, 9:15 AM EST - 7 weeks ago

Psyence BioMed Announces Settlement of Shareholder Litigation

Jan 28, 2026, 6:30 PM EST - 2 months ago

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Jan 22, 2026, 1:42 PM EST - 2 months ago

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026

Jan 20, 2026, 7:19 AM EST - 2 months ago

Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date

Jan 12, 2026, 8:30 AM EST - 2 months ago

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

Jan 5, 2026, 9:15 AM EST - 3 months ago

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

Dec 19, 2025, 7:00 AM EST - 3 months ago

Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial

Dec 9, 2025, 7:00 AM EST - 4 months ago

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Nov 25, 2025, 7:00 AM EST - 4 months ago

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Nov 20, 2025, 7:00 AM EST - 4 months ago

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Nov 12, 2025, 7:00 AM EST - 5 months ago

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Nov 6, 2025, 7:00 AM EST - 5 months ago

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Nov 3, 2025, 7:00 AM EST - 5 months ago

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

Aug 28, 2025, 8:00 AM EDT - 7 months ago

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 31, 2025, 7:30 AM EDT - 8 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jun 25, 2025, 5:00 PM EDT - 10 months ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 10 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 8:30 AM EDT - 10 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025, 8:00 AM EDT - 10 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025, 7:30 AM EDT - 11 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025, 7:30 AM EDT - 1 year ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025, 7:17 PM EDT - 1 year ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 9:39 AM EDT - 1 year ago

Psyence Group Announces Share Consolidation

Apr 15, 2025, 8:30 AM EDT - 1 year ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025, 11:18 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 1 year ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Dec 27, 2024, 4:05 PM EST - 1 year ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 23, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 17, 2024, 8:37 AM EST - 1 year ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 7:30 AM EST - 1 year ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 10, 2024, 7:30 AM EST - 1 year ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 6, 2024, 11:06 AM EST - 1 year ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 3, 2024, 7:30 AM EST - 1 year ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 25, 2024, 9:42 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Oct 14, 2024, 10:43 AM EDT - 1 year ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Oct 4, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Sep 20, 2024, 11:20 AM EDT - 1 year ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Alarusso68 Apr. 1 at 7:07 PM

$PBM this stock and company are 🐃💩

0 · Reply

Tradetime3472 Apr. 1 at 1:31 PM

0 · Reply

OwlKing Mar. 29 at 6:00 PM

$LASE $APVO $PBM $RAYA &

0 · Reply

TradeWithCreed Mar. 27 at 8:24 PM

$APVO $LASE $RAYA $PBM buls

0 · Reply

erb71 Mar. 27 at 11:21 AM

0 · Reply

Jack_Horway Mar. 27 at 2:35 AM

$PBM

0 · Reply

Itradedbadly Mar. 26 at 11:26 PM

$PBM in for 5200 shares. Will comment again when it is worth pennies or the world finally accepts psilocybin.

0 · Reply

Jbjb90 Mar. 26 at 5:21 PM

$PBM all we need is some positive news and volume and were back above 4-5

0 · Reply

Jack_Horway Mar. 16 at 4:14 PM

$PBM hlding for the long run!!!! just like bright minds!

0 · Reply

Dman_22 Mar. 15 at 9:08 PM

0 · Reply

erb71 Mar. 12 at 7:44 PM

$PBM It is intriguing that the market has yet to recognize the importance of this milestone. Perhaps it may have missed this news altogether, as implied by the minuscule volume. Anyway, it may be caught in time, as happens at many other biotech companies, where there are sometimes delays between news and market action. Let's see how it proceeds (not advice)

0 · Reply

Bikinibullshark Mar. 12 at 3:20 PM

$SPY psychedelics are great for PTSD $PBM

1 · Reply

Btolz Mar. 11 at 4:33 PM

$PBM https://finance.yahoo.com/news/corporate-psyence-biomed-advances-vertically-131500448.html

0 · Reply

Bikinibullshark Mar. 11 at 3:43 PM

$PBM good news again, and no volume 🤨

0 · Reply

Jbjb90 Mar. 11 at 1:19 PM

$PBM https://www.stocktitan.net/news/PBM/corporate-update-psyence-bio-med-advances-vertically-integrated-8uli53qnhvue.html

0 · Reply

Btolz Mar. 11 at 1:02 PM

$PBM please come out with some positive news and make this thing jump

0 · Reply

Bikinibullshark Mar. 9 at 6:49 PM

$PBM it’s ready

0 · Reply

basicgirltrading Mar. 4 at 2:56 PM

$PBM who’s going to hit the ask? Only need like 100 @ 2.60, 100 @2.64 and 100 @ 2.65 for this to jump to 2.70 and hit scanners

0 · Reply

Bikinibullshark Mar. 3 at 8:43 PM

$PBM 1 million shares. $5.4 million cash. Exporting psilocybin to Australia. Highly shorted. Hammer 🔨 on the daily. This one gonna 🏃‍♀️ soon!

1 · Reply

Jbjb90 Mar. 3 at 6:21 PM

$PBM the whole market got walloped today, released good news on a bad day, its going up from here

0 · Reply

Btolz Mar. 3 at 6:19 PM

$PBM we should see the volume increase as this news starts making its way across the web

0 · Reply

BioTuesdays Mar. 3 at 5:38 PM

$PBM has announced the export of fully GMP-compliant manufactured psilocybin product NPX-5 to Australia for the ongoing Phase 2b clinical trial evaluating natural psilocybin for the treatment of adjustment disorder in patients with cancer in a palliative care context. https://biotuesdays.com/2026/03/03/psyence-ships-gmp-compliant-psilocybin-to-australia-for-phase-2b-trial/

0 · Reply

Market Cap	2.53M
Revenue (ttm)	0.00
Net Income (ttm)	1.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	27,900
Avg Vol	232,704
Day's Range	N/A - N/A
Shares Out	1.02M
Stochastic %K	55%
Beta	0.31
Analysts	Strong Buy
Price Target	N/A